Intradermal (ID) vaccination aims at targeting the large network of skin antigen-presenting dendritic cells (DC) and constitutes a promising approach to improve anti-infectious immunity. Yet, its anti-viral protective efficacy for sub-unit vaccines and the underlying skin innate immune mechanisms remains to be explored for a wider usage in humans. Using a pig model of lethal respiratory infection with pseudorabies virus (PRV), we show that ID vaccination with adjuvant-free PRV glycoproteins triggers cellular and humoral immunity and confers protection from disease induction by nasal viral challenge, as efficiently as an oil- adjuvanted reference vaccine delivered intramuscularly.
A system (300) is disclosed for injecting a substance into a specific location within a developing avian embryo, or a specific location of an egg containing an avian embryo. The system (300) compris a means for aseptically cutting the outer shell of the egg, such that a portion of the shell is prepared for removal, a means for removing the shell portion to produce an opening in the egg, a means (303) for mapping or targeting the x, y, z coordinates of embryonic structures to locate the desired specific injection location, a means (200) for injecting the specific substance into the specific injection location, and a means for aseptically sealing the opening.
This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.
This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered
The present invention provides compositions and methods for eliciting protective immunity in animals against Leptospira Interrogans (LI) serovar copenhageni. The invention is based, in part, on the unexpected cross-protection against heterologous LI serovar, which resulted when canines were administered an effective amount of RECOMBITEK® 4 Lepto, then subsequently challenged with virulent L. copenhageni (Fiocruz Ll-130).
The present invention provides attenuated S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides novel, mutagenically-induced mutations in S. suis genes, which are useful in the production of novel attenuated S. suis bacterial strains.
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (United Kingdom)
Inventor
Palmarini, Massimo
Hudelet, Pascal
Audonnet, Jean-Christophe
Nunes, Sandro, Filipe
Abstract
The present invention encompasses BTV and ASHV vaccines or compositions and methods of producing recombinant reassortant BTV and ASHV vectors and methods of vaccination against BTV and ASHV.
The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.
Provided are improved processes for the preparation of 1 -aryl pyrazole compounds of formula (I) and (IB): which are substituted at the 5-position of the pyrazole ring with a carbon-linked functional group. The process described are efficient and scalable and do not utilize hazardous sulfenyl halide reagents.
The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.
The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.
A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
C12N 7/04 - Inactivation or attenuationProducing viral sub-units
12.
NOVEL METHODS FOR PROVIDING LONG-TERM PROTECTIVE IMMUNITY AGAINST RABIES IN ANIMALS, BASED UPON ADMINISTRATION OF REPLICATION-DEFICIENT FLAVIVIRUS EXPRESSING RABIES G
The present invention relates to compositions comprising replication defective chimeric flavivirus anti-rabies vaccines, methods of producing the vaccines, and the administration of such vaccines to companion animals, including dogs. The invention further relates to methods for providing long-term protective immunity against rabies in companion animals, including dogs and cats.
The subject matter disclosed herein is directed to stable, highly-effective topical formulations comprising permethrin, fipronil and a solvent system that is sufficient to solubilize these two active ingredients and limit degradation of fipronil to its sulfone, and their uses in topical applications on animals and the environment. Useful formulations comprise from about 30 % to about 55 % (w/w) permethrin and about 2 to 15 % (w/w) fipronil and a solvent system that comprises N-methyl pyrrolidone and a glycol, glycol ether, glycol ester, fatty acid ester or neutral oil, wherein the N-methyl pyrrolidone and glycol, glycol ether, glycol ester, fatty acid ester or neutral oil are present in a weight : weight ratio of from about 1 :2.0 to about 1 :3.5, glycol, glycol ether, glycol ester, fatty acid ester or neutral oil to n-methyl pyrrolidone. These two actives when combined in the described amounts have been found to have unexpected enhanced repellent activity against stable fly. However, it is the formulations described herein that provide solvency and stability that maintain synergistic concentrations after application on an animal.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus
The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides.
This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
The present invention relates to novel nanoencapsulated compositions, methods for making such compositions, and methods of repelling insects and other arthropod pests away from animals, including humans. The present invention has particular, though not sole, application to repelling insects including flies and mosquitoes. The inventive compositions may be used to repel arthropods from animals, humans, plants, soil, or building structures. The formulations also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents.
A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereofDerivatives thereof
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
The present invention provides for a vaccine formulation comprising plasmid DNA and a lipid adjuvant. The invention also provides for prime-boost vaccination methods wherein two sequential administration of the same plasmid-based DNA vaccine provide companion animals with protection against rabies for at least one year.
The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.
This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.
C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to an animal in need thereof.
CNRS (CENTRE NATIONAL RECHERCHE SCIENTIFIQUE) (France)
Inventor
Delaveau, Jean
Stebe, Pierre-Nicolas
Marchand-Geneste, Nathalie
Abstract
This invention relates to novel coumarin derivatives of formula (I) and formula (Ia), formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prevent illness and disease caused by insect/pest-borhe vectors, and provide safer, more effective alternatives to existing repellents. This invention also relates to novel methods for modeling and/or predicting the repellency of unknown compounds.
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
C07D 311/14 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
C07D 311/46 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring
C07D 311/52 - Enol-esters or -ethers, or sulfur analogues thereof
C07C 59/00 - Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups
A01N 31/04 - Oxygen or sulfur attached to an aliphatic side chain of a carbocyclic ring system
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
A01N 47/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
24.
PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF
This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for vitrifying biological preparations, including peptides, antigens, antibodies, cells, and the like.
A61K 9/19 - Particulate form, e.g. powders lyophilised
F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT GUSTAVE ROUSSY (France)
UNIVERSITÉ PARIS-SUD (France)
Inventor
Poulet, Hervé
Heidmann, Thierry
Abstract
The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
Inventor
Delaveau, Jean
Vialle, Emilie
Lemaire, Marc
Pellet-Rostaing, Stéphane
Andrioletti, Bruno
Abstract
This invention relates to novel coumarin derivative, formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents.
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
C07D 311/46 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring
C07C 59/00 - Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups
A01N 31/04 - Oxygen or sulfur attached to an aliphatic side chain of a carbocyclic ring system
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
28.
AMIDO-PYRIDYL ETHER COMPOUNDS AND COMPOSITIONS AND THEIR USE AGAINST PARASITES
The subject matter disclosed herein is directed to amido-pyridyl ether compounds of formula I: wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, Ra, a, b and d are as described herein, compositions comprising the compounds of formula I, methods for their preparation and methods for their uses against parasites.
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.
The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle- free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
Inventor
Maki, Joanne, L.
Fry, Tricia, Lynn
Hurley, Jerome, Cornelius
Miller, Lowell, Allen
Abstract
The present invention relates to adjuvanted recombinant anti-rabies vaccines and the oral administration of such vaccines to raccoons and other wildlife. Advantageously, the anti-rabies vaccine may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene. The invention encompasses methods of vaccinating raccoons and other wildlife by administration of an anti-rabies vaccines which may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene, in combination with an adjuvant which increases both vaccine viscosity and efficacy. The invention provides effective oral recombinant vaccines used in oral rabies vaccination (ORV) programs for wildlife, effective at protecting raccoons, gray foxes, coyotes, and other animals.
The present invention provides for an animal medicine reminder tag that is non-toxic, water resistant, and shock resistant. The tags described herein are excellent medicine compliance tools as they 1) are automatically activated when attached to the companion animal; 2) produce a persistent reminder after a manufacturer-programmed set period of time; 3) cannot be reset or turned off by the companion animal's caregiver; 4) emit the alarm/signal from both sides; 5) are sealed and non-toxic; and 6) are designed to be minimally harmful if accidentally swallowed, and may even pass safely through the gastro-intestinal tract for sufficiently large animals.
G04F 1/00 - Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
33.
TOPICAL COMBINATION FORMULATIONS OF MACROCYCLIC LACTONES WITH SYNTHETIC PYRETHROIDS
The present invention provides pyrethroid / macrocyclic lactone-containing topical formulations that are effective against animal pests, including ecto- and endoparasites. The formulations may be used for combating parasites in or on birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite and/or pest infestation of birds and mammals.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
Inventor
Delaveau, Jean
Vialle, Emilie
Lemaire, Marc
Pellet-Rostaing, Stephane
Andrioletti, Bruno
Abstract
This invention relates to novel polyether ionophores, formulations comprising same, and to methods of making and using these compounds and formulations for the treatment and/or prevention of parasitic infection in animals and humans. These compounds exhibit improved safety profiles and/or efficacies as compared to parent compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Fischer, Laurent Bernard
Kamahwi, Shaden
Valenzuela, Jesus
Suau, Hamide Aslan
Abstract
The present invention provides a method for effectively and reproducibly infecting canines with Leishmania infantum using sand flies to vector the parasite. The inventive method comprises several steps, including ensuring canines are naive to Leishmania, infecting the canines using bites of Leishmania-infected sand fly bites, and evaluating successful transmission of the Leishmania parasites.
The invention relates to an intraruminal sustained release capsule which is capable of delivering a sustained release dose of a first medicament to an animal, as well as either or both of a dump dose of a second medicament or mineral, and an exit dose of a third medicament or mineral. The capsule can have a dissolvable overcap molded from plasticized starch enabling a dump dose of medicament to be held between the overcap and one end of the capsule. A piston within the body of the capsule can be modified to enable it to accommodate an exit dose of medicament within its hollow interior which is aligned with an aperture at the end of the capsule which enables release of the medicaments to the rumen. After insertion of the capsule in the animal the overcap (if present) dissolves and separates from the capsule to release the dump dose of medicament. The sustained release medicament is then dispensed via the apertured end, followed by the release of the exit dose of medicament (if present).
The application discloses therapeutic vaccines based upon the "pING" DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and prolong the post-surgical disease free interval and/or survival time. Also included are therapeutically effective methods of immunization using said vaccines.
The present invention encompasses recombinant Newcastle Disease Virus - Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.
The present invention provides levamisole / macrocyclic lactone-containing injectable formulations that are effective against animal pests, including endoparasites. The formulations may be used for combating parasites in or on birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation of birds and mammals.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/00 - Medicinal preparations characterised by special physical form
This invention relates to compositions for combating ectoparasites and endoparasites in animals, comprising at least one 1-arylpyrazole, at least one macrocyclic lactone, at least one insect growth regulator, and at least one anthelmintic compound in combination with a pharmaceutically acceptable carrier. This invention also provides for an improved method for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or porcines, against FMDV.
The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV.
The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.
The present invention encompasses NDV vaccines. The vaccine may be a subunit vaccine based on HN of NDV. The NDV HN may be expressed in plants or algae including microalgae. The invention also encompasses recombinant vectors encoding and expressing NDV antigens, epitopes or immunogens which can be used to protect animals against NDV. It encompasses also a vaccination regime compatible with the DIVA strategy, including a prime-boost scheme using viral vector or inactivated vaccines and subunit vaccines.
The present invention is directed to recombinant microalgal cells and their use production of heterologous hemagglutinin-neuraminidase (HN) polypeptides, as well compositions and uses thereof.
The present invention provides formulations which may comprise macrocyclic lactones and at least one spirodioxepinoindole derivative or a spirooxepinoindole derivative for combating parasites in birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present invention relates to novel dihydroazole of formula (I) and salts thereof: Wherein R1, A1, A2, G, X and Y are as defined in the description, compositions thereof, processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present invention provides bis-organosulfur compounds of formulae (I) and (II) and compositions comprising the compounds that are effective against animal pests, including parasites. The compounds and compositions may be used for combating parasites in or on birds and mammals and for combating pests that damage crops, plants and plant propagation material. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
C07C 323/60 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
C07C 323/65 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
C07C 327/42 - Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
49.
FLUORINATED OXA OR THIA HETEROARYLALKYLSULFIDE DERIVATIVES FOR COMBATING INVERTEBRATE PESTS
The invention relates to alkylsulfide derivatives compounds of formula I as hererunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to methods for controlling invertebrate pests by using these compounds and to plant propagation material and to agricultural and veterinary compositions comprising said compounds. wherein U, R1, R2, R3U, X, n and p are defined as in the description.
DICYCLANIL-BASED AQUEOUS SUSPENSION AND NON-AQUEOUS SOLUTION POUR-ON AND SPRAY ON FORMULATIONS FOR THE PREVENTION AND TREATMENT OF INSECT INFESTATION IN ANIMAL
This invention relates to topically active compositions, including pour-on and spray- on formulations, comprising insect growth regulator (IGR) insecticides prepared as aqueous suspension formulations, or as non-aqueous solution formulations, and to the methods of making these formulations, and to methods of using these formulations for the treatment and/or prevention of insect infestation in animals.
The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
Inventor
Bublot, Michel
Mebatsion, Teshome
Pritchard, Joyce
Mundt, Egbert
Abstract
The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV.
The invention relates to an intraruminal sustained release capsule which is capable of delivering a sustained release dose of a first medicament to an animal, as well as either or both of a dump dose of a second medicament or mineral, and an exit dose of a third medicament or mineral. The capsule can have a dissolvable overcap moulded from plasticised starch enabling a dump dose of medicament to be held between the overcap and one end of the capsule. A piston within the body of the capsule can be modified to enable it to accommodate an exit dose of medicament within its hollow interior which is aligned with an aperture at the end of the capsule which enables release of the medicaments to the rumen. After insertion of the capsule in the animal the overcap (if present) dissolves and separates from the capsule to release the dump dose of medicament. The sustained release medicament is then dispensed via the apertured end, followed by the release of the exit dose of medicament (if present).
Insecticidal 4-Amino--thieno[2,3-d]-pyrimidine compounds and methods of their use to control pests that damage plants and crops and parasites that harm animals. The present invention relates to new insecticidal 4-Amino--thieno[2,3-d]-pyrimidine compounds and new methods of their use. The new 4-Amino--thieno[2,3-d]-pyrimidine derivatives have formula (I), wherein X, R1, R2, R3 and A are defined as in the description. The invention relates also to their enantiomer, diastereomer or agriculturally or veterinary acceptable salt thereof. The invention relates also to agricultural and veterinary compositions comprising such compounds. The invention relates further also to different insecticidal methods applying such compounds and compositions.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, and a salt of a compound of formula (I).
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formulations and/or compositions comprising a protein or an immunogen expressed using the drugless plasmids, and methods of administering such formulations and/or compositions to a host. The invention relates to gram negative bacteria containing the drugless plasmids.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 39/00 - Medicinal preparations containing antigens or antibodies
58.
MACROCYCLIC LACTONE COMBINATION COMPOSITIONS, VACCINES AND METHODS FOR PRODUCING SAME
An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.
The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
This invention provides for novel antiparasitic and pesticidal derivatives of avermectin and milbemycin compounds in which two avermectin or milbemycin members are linked together by a chemical linker. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections and infestations in animals or for combating pests in plants or plant propagation material.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
This invention provides for novel antiparasitic and pesticidal derivatives of avermectin and milbemycin compounds in which two avermectin or milbemycin members are linked together by a chemical linker. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections and infestations in animals or for combating pests in plants or plant propagation material.
C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
C07H 19/01 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof sharing oxygen
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present invention relates to veterinary or pharmaceutical formulations comprising one or more plant oils and bismuth subnitrate and methods for their manufacture and uses. The formulations are useful as a teat sealant to prevent or treat mastitis in an animal.
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
63.
RECOMBINANT AVIAN INFLUENZA VACCINE AND USES THEREOF
The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a subunit vaccine based on the hemagglutinin of influenza. The hemagglutinin may be expressed in plants including duckweed. The invention also encompasses recombinant vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals against influenza. It encompasses also a vaccination regimen compatible with the DIVA strategy, including a prime-boost scheme using vector and subunit vaccines.
This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to the animal in need thereof.
This invention provides for dimericl-arylpyrazole compounds, of formulas (I), (II), and or salts thereof, and the use of these compounds against ectoparasites such as insects, arthropods and acarina. The resulting compounds may be used in veterinary formulations such as, for example, spot-on and pour-on formulations, which may be used for treatment, controlling and preventing of parasitic infections in warm-blooded animals and birds.
The present invention relates to veterinary or pharmaceutical formulations which may comprise ceftiofur, ketoprofen, benzyl alcohol, or effective combinations thereof. The formulations of the present invention may include a wetting or dispersing agent, a preservative, a flocculating agent or resuspendability enhancer, and/or a biocompatible oil vehicle. This invention also provides for, inter alia, formulations for the treating, controlling and preventing of respiratory disorders, particularly bovine respiratory disease (BRD), in warm-blooded animals, such as livestock,. This invention further provides for methods of increasing the resuspendability of an oily formulation which may comprise the addition.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
67.
Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to the animal in need thereof.
The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula (I): wherein R3, R4, R5, R6, R7, R13a, R13b, R14a, R14b, P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
The present invention relates to novel thioamide derivatives of formula (I) and formula (Ia): wherein, R3, R4, R5, R6, R7, P, Q, T, V, W, X, Y, Z, a, m and n are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.
The present invention relates to methods for synthesizing macrolide compounds which are known to have antibacterial activity, and are useful in the therapy of bacterial infections in mammals. More specifically, the invention relates to methods for synthesizing the macrolide antibiotic, gamithromycin utilizing a novel configuration of catalysts, chemical structures, and/or methods. An embodiment of the present invention may include allowing multiple chemical reactions to proceed without the isolation of chemical intermediates. Thus, multiple reactions may occur in one reaction vessel allowing for a considerable decrease in the cycle-time. The present invention also provides a novel method for inhibiting degradation while isolating a structure of a pharmaceutical composition.
The invention relates to a method for purifying trifluoromethanesulfinic acid by azeotropic distillation using an aromatic solvent, to a method for producing purified trifluoromethanesulfinic acid, and to the use of the purified trifluoromethanesulfinic acid for the production of trifluoromethylsulfinylated pyrazole derivatives, in particular fipronil.
The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals, such as livestock.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01P 15/00 - Biocides for specific purposes not provided for in groups
74.
METHODS FOR ENHANCING THE STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
75.
Leishmania vaccine using sand fly salivary immunogen
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
76.
LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN
THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (USA)
Inventor
Fischer, Laurent, Bernard
Valenzuela, Jesus, G.
Abstract
The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use with such methods and compositions.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A trigger operated syringe (100) for intramammary injection of antibiotics has a fluid containing syringe cartridge (203) activated by a plunger (206) which is inserted into the syringe cartridge (203A) and expels fluid when the trigger (205) is pulled. A syringe cartridge holding mechanism (223) holds the syringe cartridge in place until the trigger (205) is released and the plunger (206) retracted. Single syringe cartridge (203) and multiple syringe cartridge (204) versions are disclosed. The plunger moves in a direction which is effectively perpendicular to the direction of movement of the trigger, allowing for ease of injection to a cow's teats, and ejection of the spent cartridges.
3 and A are defined as in the description. The present invention relates to insecticidal methods of applying such compounds of formula (I), and to new derivatives of compounds of formula (I).
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.
The presence of horns within commercial cattle populations increases the chances of injuries. The Polled (hornless) condition in cattle has existed since domestication, and it has been selected by breeders because of its economic importance and ease of management. A dominant mutation is believed to cause the polled phenotype. The present invention relates to the identification of breed- specific single nucleotide polymorphisms (SNPs) and their haplotypes, in the bovine genome, in or near gene(s) encoding polypeptides associated with the Polled phenotyped in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data, haplotype data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable productions quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field location.
This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on formulations comprising a composition comprising a flukicide, such as, for example, clorsulon (4-amino-6-trichloroethenyl- 1,3 -benzene disulfonamide) and/or a macrolide anthelmintic or antiparasitic agent. In other embodiments, the invention provides pour-on formulations comprising at least one active agent, a glycol ether, and a stability enhancer. This invention also provides for methods for eradicating, controlling, and/or preventing parasite infestation in animals, such as cattle and sheep.
The invention relates to a method for producing the flu virus, that comprises: a) administering a flu vaccine to hens; b) collecting the eggs of the vaccinated hens; c) triggering the embryogenesis process; d) infecting the embryonated eggs by inoculating a flu virus in the allantoic cavity; e) incubating the infected embryonated eggs in temperature and humidity conditions allowing the virus replication; and f) collecting the allantoic liquid containing the virus.
The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of osteoarthritis in mammals, advantageously in humans, dogs, horses and cats, by intraarticular administration of the recombinant vectors and pharmaceutical compositions of the invention.
The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in dogs and cats, by administration of the recombinant vectors and pharmaceutical compositions of the invention.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
85.
SYSTEMS AND METHODS FOR PREDICTING A LIVESTOCK MARKETING METHOD
The present invention is directed to methods and systems for improving the efficiency of livestock production using genetic information obtained from the animal. The methods of the invention comprise obtaining a genetic sample from an animal or embryo, determining the genotype of the animal or embryo with respect to specific quality traits, grouping animals with like genotypes, and optionally, further sub-grouping animals based on like phenotypes. The invention is further directed to a method of predicting the carcass quality of an animal by correlating the rate of change in carcass traits with the genotype of the animal.
The present application is based on the development of a technology related to plant transformation and to the expression of non-plant proteins in a plant host, hi particular, the technology can be used for the generation of transgenic plants that can express and produce animal proteins useful for inducing an immune response against viruses. One such virus is porcine circovirus type II (PCVII), which has been associated with diseases such as postweaning multisystemic wasting syndrome (PMWS) that threatened swine populations. Provided is a transgene construct that can be used in the transformation of a plant host, and the gene expression products expressed by the transformed plants. Also provided are immunogenic compositions and vaccines, vaccine kits, and immunization or vaccination methods that make it possible to use such immunization or vaccination programs.
The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I):wherein R3, R4, R5, R6, R7, P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
C07C 253/04 - Preparation of carboxylic acid nitriles by reaction of cyanogen halides, e.g. ClCN, with organic compounds
C07C 255/42 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
A01N 43/707 - 1,2,3- or 1,2,4-TriazinesHydrogenated 1,2,3- or 1,2,4-triazines
Provided is a novel ivermectin derivative and compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise: (A) a pharmaceutically effective amount of a 1-N-phenylpyrazole compound; (B) a pharmaceutically effective amount of an ivermectin derivative of formula (II) wherein: R 14 represents -(CH2)S-O-Z wherein, s is 1 or 2; Y represents -CH(OR, 15)-, -C(=O)- or -C(=NOR 15); R15 represents hydrogen, alkyl or phenyl; and R16 represents -CH3 or -CH2CH3; Z is alkyl, alkenyl, alkynyl, acyl, alkylalkoxy, aryl, alkanoyloxy, alkoxycarbonyl, alkenoyl, alkynoyl, or aroyl.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
The present invention relates to compositions and methods to improve expression of exogenous polypeptides, such as an antigen, epitope, immunogen, peptide or polypeptide of interest. More particularly, the present invention provides for DNA plasmids with increased expression and stability in compositions and methods useful for DNA vaccines.
The assemblies of the invention are suitable for mounting to or being an Integral part of, an animal enclosure such that the height of a valve-controlled liquid outlet may be adjusted according to the changing needs of growing animals The adjustable liquid delivery assemblies comprise an elongated rail, a liquid delivery unit having at least one liquid delivery head slideably engaged with the elongated rail, a flexible liquid delivery tube for connecting a liquid delivery head to a liquid source, and a means for securing the liquid delivery unit at a selected position on the elongated rail The liquid delivery system may further comprise a retaining rail A means for securing the liquid delivery unit at a selected position on the elongated rail may comprise a linear series of holes disposed along the length of the rail.
The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against vesicular stomatitis virus (VSV) in an animal susceptible to VSV. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain at least one heterologous nucleic acid molecule(s), expresses in vivo in the animal VSV antigen(s), immunogen(s) or epitope(s) thereof, e.g., VSV G protein and/or VSV N protein and/or VSV M protein. The heterologous nucleic acid molecule(s) may be adjusted to the vector/mammalian cell system by codon optimization. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.
The present invention provides an injection delivery system for the injection delivery of at least two fluid doses to a small bird by penetrating the skin of the recipient bird with at least on injection needle. The present injection delivery system comprises an injection needle device and a metering device. The injection needle device can either be a stationary unit or a hand held device.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
This invention provides for a pharmaceutical or veterinary paste or gel formulation which may comprise an effective amount of a therapeutic agent; optionally an absorbent or a viscosity modifier; optionally a hydrophilic carrier, a colorant, stabilizer, surfactant, or preservative and optionally an antioxidant, solvent, flavoring, buffering system or thickener and methods of preparing these formulations. This invention also provides for, inter alia, oral homogeneous veterinary pastes or gels for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals, such as birds, horses and household pets.
A liquid veterinary formulation comprising a stable solution of 6% cyromazine w/v in a solvent system containing water and from 30% to 99% of one or more of the polyethylene glycols. A liquid concentrate is also described in which the cyromazine is dissolved in a liquid PEG and is capable of being diluted with water from 1% v/v to 70% v/v before use.
A01N 43/68 - 1,3,5-Triazines, not hydrogenated and not substituted at the ring nitrogen atoms with two or three nitrogen atoms directly attached to ring carbon atoms
The present invention relates to the field of vaccination against Salmonella in animals, particularly avian animals. The present invention also encompasses kits and uses of Salmonella immunogenic compositions or vaccines. The present invention further relates to methods and compositions comprising at least one primo-administration of an attenuated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle and at least one attenuated Salmonella, administered to an avian animal before at least one boost-administration of an inactivated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle, and at least one inactivated Salmonella.
The present invention encompasses a flow-through dispersion device for the dispersion of cell aggregates, the device comprising a first or upstream inlet obstacle and a second or downstream outlet obstacle, each obstacle having at least one traversing hole wherein no two holes align. Between the two obstacles is a turbulence chamber, such that when a cell suspension is passed through the inlet holes, into the chamber and then exits the second obstacle, the turbulence within the chamber disrupts and disperses cell aggregates. The device optionally may have more than two obstacles and turbulence chambers and multiple units may be placed in series to increase the amount of turbulence and time applied to a volume of cells. The invention further encompasses methods of using the device to disperse cell aggregates, and methods of culturing cells that involve seeding cultures and maintaining dispersed individual cells.
The present invention provides vectors that contain and express in vivo Leishmania KMP11 or an epitope thereof that elicits an immune response in a dog against Leishmania, compositions comprising said vectors, methods of vaccination against Leishmania, and kits for use with such methods and compositions.
The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in humans, dogs and cats, by intra-vascular kidney administration of the recombinant vectors and pharmaceutical compositions of the invention.
The invention relates to 5-diazacycloalkylpyrazole derivatives of the formula (I) or salts thereof a process for their preparation, to compositions thereof and to their use for the control of pests, including arthropods and helminths
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against avian influenza.
patents
